Key facts
- This page summarizes Damien McDevitt's Form 3 filing for Aspen Neuroscience, Inc..
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 29 Oct 2026, 20:04.
Key filing fact
Ownership activity is grounded in SEC Form 3 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No transaction description listed
No transaction description listed
Additional SEC filing notes
Footnote F1
Shares of Common Stock held by Damien McDevitt and Pamela Marnell-McDevitt, Co-trustees of the Marnell-McDevitt Family Trust dated May 2, 2019, of which 93,607 shares remain subject to performance-based vesting conditions and to repurchase by the Issuer if such conditions are not met or upon termination of the Reporting Person's service.
Footnote F2
Shares of Common Stock held by Finn McDevitt, Trustee of the Finn McDevitt 2025 Irrevocable Trust.
Footnote F3
Shares of Common Stock held by Aran McDevitt, Trustee of the Aran McDevitt 2025 Irrevocable Trust.
Footnote F4
Shares of Common Stock held by Conor McDevitt, Trustee of the Conor McDevitt 2025 Irrevocable Trust.
Footnote F5
The option was granted on December 16, 2024. The option is fully vested and exercisable.
Footnote F6
The option was granted on November 26, 2025. The shares subject to the option were previously eligible to vest in 48 equal monthly installments beginning on December 20, 2025. In August 2026, the vesting schedule was amended such that the unvested shares subject to the option as of July 20, 2026, shall vest in equal monthly installments through November 20, 2031, subject to the Reporting Person's continuous service through each vesting date.
SEC remarks
Exhibit 24 - Power of Attorney President and Chief Executive Officer